Literature DB >> 29508764

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Linda Dirven1, Terri S Armstrong2, Jaishri O Blakeley3, Paul D Brown4, Robin Grant5, Rakesh Jalali6, Heather Leeper7, Tito Mendoza8, Lakshmi Nayak9, Jaap C Reijneveld10, Emilie Le Rhun11, Tobias Walbert12, Michael Weller13, Patrick Y Wen14, Martin J B Taphoorn15.   

Abstract

The Response Assessment in Neuro-Oncology-Patient-Reported Outcome (RANO-PRO) working group is an international multidisciplinary collaboration that provides guidance on the use of patient-reported outcome (PRO) measures in clinical trials and practice for adult patients with brain tumours. Findings from both PROs and traditional outcome measures, such as survival, and clinical or radiological response, are essential to inform the research community, policy makers, physicians, and patients in the treatment decision-making process. Previous initiatives in oncology have focused on guidelines concerning the collection, analysis, interpretation, and reporting of PRO data. However, we recommend the application of appropriate PRO instruments, with respect to its content and measurement properties (ie, research question, content validity, and other measurement properties), in brain tumour research. PROs should be well defined and reliable to generate high-quality evidence, and our recommendations on the use of specific PRO measures could help to improve the quality of PRO evidence derived from neuro-oncological studies, and might add a new dimension in how the value of therapeutics is assessed in patients with brain tumours. In this Policy Review, we present the RANO-PRO working plan for the use of PROs in adults with brain tumours.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29508764     DOI: 10.1016/S1470-2045(18)30004-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  13 in total

Review 1.  Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement.

Authors:  James M Snyder; Jacob A Pawloski; Laila M Poisson
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 2.  Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials.

Authors:  Emanuela Molinari; Tito R Mendoza; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2018-08-07

3.  Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.

Authors:  Karin Piil; Meagan Whisenant; Tito Mendoza; Terri Armstrong; Charles Cleeland; Sara Nordentoft; Loretta A Williams; Mary Jarden
Journal:  Neurooncol Pract       Date:  2020-10-19

4.  Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.

Authors:  Louis Garnier; Emilie Charton; Antoine Falcoz; Sophie Paget-Bailly; Dewi Vernerey; Marine Jary; François Ducray; Elsa Curtit
Journal:  Neurooncol Pract       Date:  2020-11-11

Review 5.  Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.

Authors:  Christopher P Millward; Terri S Armstrong; Heather Barrington; Andrew R Brodbelt; Helen Bulbeck; Anthony Byrne; Linda Dirven; Carrol Gamble; Paul L Grundy; Abdurrahman I Islim; Mohsen Javadpour; Sumirat M Keshwara; Sandhya T Krishna; Conor L Mallucci; Anthony G Marson; Michael W McDermott; Torstein R Meling; Kathy Oliver; Barry Pizer; Puneet Plaha; Matthias Preusser; Thomas Santarius; Nisaharan Srikandarajah; Martin J B Taphoorn; Colin Watts; Michael Weller; Paula R Williamson; Gelareh Zadeh; Amir H Zamanipoor Najafabadi; Michael D Jenkinson
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

6.  Unmet needs and recommendations to improve meningioma care through patient, partner, and health care provider input: a mixed-method study.

Authors:  Amir H Zamanipoor Najafabadi; Johannes P M van de Mortel; Daniel J Lobatto; Dieta R Brandsma; Wilco C Peul; Nienke Biermasz; Martin J B Taphoorn; Linda Dirven; Wouter R van Furth
Journal:  Neurooncol Pract       Date:  2019-11-02

7.  Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma.

Authors:  Lena Rosenlund; Eskil Degsell; Asgeir Store Jakola
Journal:  Patient Relat Outcome Meas       Date:  2019-08-23

Review 8.  Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review.

Authors:  Marijke B Coomans; Marthe C M Peeters; Johan A F Koekkoek; Jan W Schoones; Jaap Reijneveld; Martin J B Taphoorn; Linda Dirven
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

Review 9.  Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative.

Authors:  Linda Dirven; Maartje E Vos; Tobias Walbert; Terri S Armstrong; David Arons; Martin J van den Bent; Jaishri Blakeley; Paul D Brown; Helen Bulbeck; Susan M Chang; Corneel Coens; Mark R Gilbert; Robin Grant; Rakesh Jalali; Danielle Leach; Heather Leeper; Tito Mendoza; Lakshmi Nayak; Kathy Oliver; Jaap C Reijneveld; Emilie Le Rhun; Larry Rubinstein; Michael Weller; Patrick Y Wen; Martin J B Taphoorn
Journal:  Neurooncol Pract       Date:  2021-02-13

Review 10.  Clinical Trial Considerations in Neuro-oncology.

Authors:  Eudocia Q Lee
Journal:  Curr Treat Options Oncol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.